Iceland
Country
Alvotech is shifting toward dual-source manufacturing and operational execution as it addresses FDA setbacks, expands its biosimilar pipeline and drives growth through global launches, with US approvals representing key upside to its 2026 outlook.
Nearly 50 medicines are now included in a Nordic pilot that relaxes language requirements on packaging to help improve access to essential hospital treatments.
Standing “shoulder to shoulder” can help alleviate difficult global market conditions, according to the Joint Nordic HTA Body.
Positive results from a randomized study in healthy volunteers mark a key milestone for Alvotech’s proposed Entyvio rivals AVT80 and AVT16.
Speaking exclusively to Generics Bulletin, Alvotech’s founder Robert Wessman explains why the company’s leadership split and Lisa Graver’s Iceland-based appointment as CEO mark a pivotal moment in its operational evolution.
What exactly is causing Alvotech’s frustrating list of US complete response letters? In a recent call with investors, management shed light on the company’s issues.
Alvotech has unveiled a planned leadership transition, with founder and chairman Róbert Wessman handing the chief executive role to long-time collaborator Lisa Graver as the biosimilars specialist prepares for its next phase of growth.
Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
Drug companies are being invited to participate in a new pilot project that the five Nordic countries will run to see if they can improve the availability of certain critical products that are used in hospitals.
European cross-country HTA collaborations have much to learn from each other to keep prices from rising unfairly, Nordic health technology assessment experts say, adding that talks on collaboration are also ongoing with HTA bodies outside the continent.
European cross-country HTA collaborations have much to learn from each other to keep drug prices from rising unfairly, Nordic health technology assessment experts say, adding that talks on collaboration are also ongoing with HTA bodies outside the continent.